Navigation Links
Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities
Date:11/3/2008

HAYWARD, Calif., Nov. 3 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that two of its programs (MBX-2982 and MBX-8025) have been recognized in Windhover's "Top 10 most interesting projects available for partnering" in their respective categories. MBX-2982, a potential first-in-class treatment for type 2 diabetes, was recognized in the metabolic category and MBX-8025, a potential treatment for a range of dyslipidemias, was recognized in the cardiovascular category. The selections were made by independent committees assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries.

"We are honored to receive this significant recognition for not one, but two of our current programs. This recognition underscores both MBX-2982's potential to become an important new therapy for type 2 diabetes, and MBX-8025's potential in the treatment of dyslipidemia," said Harold Van Wart, Ph.D., Chief Executive Officer of Metabolex.

The metabolic selection committee was led by Marc Wortman, contributing writer to Windhover's IN VIVO and Start-Up, and Harris Kaplan, President & CEO, and Jun Huangpu, Managing Director, of Healogix, a leading business development strategy consulting firm. The cardiovascular selection committee was led by Ed Saltzman, President, and Michael Rice, Senior Consultant, of Defined Health, a leading business development strategy consulting firm.

Drawing on the analytic resources of these organizations, the selection committees evaluated hundreds of compounds currently in development.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive metabolic and cardiovascular
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Metabolex Names Zhao, Martin to Executive Posts
2. Metabolex Appoints Donald Hill as Chief Financial Officer
3. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
4. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
5. Maryland Stem Cell Research Commission Recommends 62 Projects for Funding
6. JIC Invests in Three New Alternative Energy Projects
7. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
8. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
9. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Huge event with 36,000+ global professionals is ... analysis and forecasting   CPhI Worldwide , ... most successful show to date with pre-audit figures estimating ... year in Paris , the show ... countries representing every step of the pharmaceutical supply chain ...
(Date:10/31/2014)... Ill. (PRWEB) October 31, 2014 Jeffrey ... Department of Historical Studies within the College of Arts ... SIUE to record the history of alcohol-based fuels in ... and many others have been working to build Illinois’ ... important but overlooked aspect of the state's agricultural and ...
(Date:10/31/2014)... 31, 2014 ENVIRON , ... announced today that Dr. Harvey Clewell III has ... will work closely with senior professionals in ENVIRON’s ... to serve at The Hamner Institutes for Health ... Carolina, where he is Director, Center for Human ...
(Date:10/30/2014)... LONDON , October 30, 2014 ... Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... PCYC ), Synthetic Biologics Inc. (NYSE MKT: SYN), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,549.23, down 0.33%, the Dow Jones ...
Breaking Biology Technology:CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... ... Capital,s client Neuren Pharmaceuticals Ltd (ASX:NEU) has agreed an AU$6.7 mil convertible note private ... as Neuren,s exclusive placement agent and advisor. , ... New York (PRWEB) November 23, 2009 -- The independent ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced that it has ... common stock will be,suspended as of November 30, 2009 and a ... will remove deCODE,s common stock,from listing on Nasdaq, unless the company ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced the approval of all of ... Delaware,(the "Bankruptcy Court"). deCODE last week filed a voluntary petition for,relief under ... The orders issued by the Bankruptcy Court allow ...
Cached Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
(Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
(Date:10/29/2014)... and gas production are well over recommended levels in ... journal Environmental Health . High levels of benzene, ... the first to be based on community sampling by ... used to supplement official air-quality monitoring programs. , Unconventional ... readily flow to the surface. This is because they ...
(Date:10/29/2014)... been blamed for increasing the risk of a ... history of schizophrenia, are widely accepted. Others, such ... parasite transmitted by soil, undercooked meat and cat ... new study by Gary Smith, professor of population ... School of Veterinary Medicine, used epidemiological modeling methods ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... developed a small-molecule inhibitor of a protein that plays ... they show that the inhibitor can halt the growth ... culture. The findings are reported in companion papers reported ... Jan-Michael Peters of the Research Institute of Molecular Pathology ...
... developed at the University of Toronto is revealing biochemical ... could one day pave the way for pharmaceutical applications. ... issue of Molecular Cell describes how U of T ... test for proteins that play an important role in ...
... popular game fish mistaken by scientists for a dog ... reefs of the Abrolhos region of the South Atlantic ... discovery of Lutjanus alexandrei, a new snapper species that ... of Conservation International (CI) and Kenyon Lindeman of Environmental ...
Cached Biology News:New protein inhibitor impedes growth of cancerous cells 2Technology reveals 'lock and key' proteins behind diseases 2New species of snapper discovered in Brazil 2
... mg/L sodium pyruvate, 50 mg/L streptomycin sulfate, ... calcium chloride, and magnesium chloride. The use ... tissue culture is generally attributed to early ... Ringer developed a solution of inorganic salts ...
... dramatic breakthrough in accurate, small-volume bulk dispensing. Dispensing ... micro 1 has unique advantages not found in ... never needs re-calibration as do other 1mL dispensers. ... LCD Display , Graphical Row Selection , 96-,384- ...
... Rabbit polyclonal to Rad51 ( Abpromise ... Antigen: Synthetic peptide: ... N terminal amino acids 15-29 of ... Gene ID: 5888 ...
... performance agitation and temperature control for microbiology ... wells independently and is suitable for DASGIP ... working volume. Its temperature ranges from approximately ... well is equipped with an individual electrical ...
Biology Products: